Toshiyasu Sasaoka

Summary

Affiliation: University of Toyama
Country: Japan

Publications

  1. Onogi Y, Wada T, Kamiya C, Inata K, Matsuzawa T, Inaba Y, et al. PDGFR? Regulates Adipose Tissue Expansion and Glucose Metabolism via Vascular Remodeling in Diet-Induced Obesity. Diabetes. 2017;66:1008-1021 pubmed publisher
    ..Therefore, PDGF-B-PDGFR? signaling plays a significant role in the development of adipose tissue neovascularization and appears to be a fundamental target for the prevention of obesity and type 2 diabetes. ..
  2. Wada T, Ishikawa A, Watanabe E, Nakamura Y, Aruga Y, Hasegawa H, et al. Eplerenone prevented obesity-induced inflammasome activation and glucose intolerance. J Endocrinol. 2017;235:179-191 pubmed publisher
    ..Therefore, we consider MR to be a crucial target to prevent metabolic disorders by suppressing inflammasome-mediated chronic inflammation in the adipose tissue and liver under obese conditions. ..
  3. Tsuneki H, Yoshida H, Okamoto K, Yamaguchi M, Endo K, Nakano A, et al. AS1949490, an inhibitor of 5'-lipid phosphatase SHIP2, promotes protein kinase C-dependent stabilization of brain-derived neurotrophic factor mRNA in cultured cortical neurons. Eur J Pharmacol. 2019;851:69-79 pubmed publisher
    ..Therefore, inhibition of SHIP2 appears to be valuable therapeutic strategy against neurological disorders associated with insufficient BDNF functions. ..
  4. Tsuneki H, Sasaoka T, Sakurai T. Sleep Control, GPCRs, and Glucose Metabolism. Trends Endocrinol Metab. 2016;27:633-642 pubmed publisher
    ..In this review we focus on the beneficial impact of sleep on glucose metabolism and suggest a possible strategy for therapeutic intervention against sleep-related metabolic disorders. ..
  5. Tsuneki H, Yoshida H, Endo K, Mori N, Hosoh S, Tsuda M, et al. Different impacts of acylated and non-acylated long-acting insulin analogs on neural functions in vitro and in vivo. Diabetes Res Clin Pract. 2017;129:62-72 pubmed publisher
    ..These pharmacological profiles should be taken into account for developing an insulin-based therapy to treat Alzheimer's disease. ..